1 Title page

- 2 Title
- 3 Characterising heterogeneity and sero-reversion in antibody responses to mild SARS^{II}CoV-2
- 4 infection: a cohort study using time series analysis and mechanistic modelling

5 Authors

- 6 Manisty C^{1,2}, Treibel TA^{1,2}, Jensen M², Semper A³, Joy G², Gupta RK⁴, Cutino-Moguel T⁵,
- 7 Andiapen M⁶, Jones J³, Taylor S³, Otter A³, Pade C⁷, Gibbons JM⁷, Lee WYJ⁷, Jones M⁸,
- 8 Williams D^{9,10}, Lambourne J¹¹, Fontana M^{12,13}, Altmann DM¹⁴, Boyton RJ¹⁵, Maini MK⁴, McKnight A⁸,
- 9 Brooks T³, Chain B⁴, Noursadeghi M^{*4,} Moon JC^{*1,2} on behalf of COVIDsortium Investigators

10 Affiliations

- 11 ^{1.} Institute of Cardiovascular Sciences, University College London, London, UK
- 12 ^{2.} Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK, London, UK
- ^{3.} National Infection Service, Public Health England, Porton Down, UK
- ^{4.} Division of Infection and Immunity, University College London, London, UK
- 15 ^{5.} Department of Virology, Barts Health NHS Trust, London, UK
- ^{6.} Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, London, UK
- ^{7.} Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
- ^{8.} Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and 24
 Dentistry, Queen Mary University of London, London, UK
- ^{9.} MRC Unit for Lifelong Health and Ageing, University College London, London, UK
- 23 ^{10.} Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- 24 ^{11.} Department of Infection, Barts Health NHS Trust, London, UK
- 25 ^{12.} Royal Free London NHS Foundation Trust, London, UK
- 26 ^{13.} Division of Medicine, University College London, London, UK
- 27 ^{14.} Department of Immunology and Inflammation, Imperial College London, London, UK
- 28 ^{15.} Department of Infectious Disease, Imperial College London, London, UK
- 29 * These authors made an equal contribution.

30 Correspondence

- 31 Professor Mahdad Noursadeghi, Division of Infection and Immunity, University College London.
- 32 Email:

m.noursadeghi@ucl.ac.uk

33 Abstract

34 Background

SARS-CoV-2 serology is used to identify prior infection at individual and at population level. Extended longitudinal studies with multi-timepoint sampling to evaluate dynamic changes in antibody levels are required to identify the time horizon in which these applications of serology are valid, and to explore the longevity of protective humoral immunity.

39 Methods

Health-care workers were recruited to a prospective cohort study from the first SARS-CoV-2 epidemic
peak in London, undergoing weekly symptom screen, viral PCR and blood sampling over 16-21
weeks. Serological analysis (n=12,990) was performed using semi-quantitative Euroimmun IgG to
viral spike S1 domain and Roche total antibody to viral nucleocapsid protein (NP) assays.
Comparisons were made to previously reported pseudovirus neutralising antibody measurements.

45 Findings

46 A total of 157/729 (21.5%) participants developed positive SARS-CoV-2 serology by one or other 47 assay, of whom 31.0% were asymptomatic and there were no deaths. Peak Euroimmun anti-S1 and 48 Roche anti-NP measurements correlated (r=0.57, p<0.0001) but only anti-S1 measurements 49 correlated with near-contemporary pseudovirus neutralising antibody titres (measured at 16-18 50 weeks, r=0.57, p<0.0001). By 21 weeks' follow-up, 31/143 (21.7%) anti-S1 and 6/150 (4.0%) anti-NP 51 measurements reverted to negative. Mathematical modelling suggested faster clearance of anti-S1 52 compared to anti-NP (median half-life of 2.5 weeks versus 4.0 weeks), earlier transition to lower levels 53 of antibody production (median of 8 versus 13 weeks), and greater reductions in relative antibody 54 production rate after the transition (median of 35% versus 50%).

55 Interpretation

56 Mild SARS-CoV-2 infection is associated with heterogenous serological responses in Euroimmun 57 anti-S1 and Roche anti-NP assays. Anti-S1 responses showed faster rates of clearance, more rapid 58 transition from high to low level production rate and greater reduction in production rate after this 59 transition. The application of individual assays for diagnostic and epidemiological serology requires 60 validation in time series analysis.

61 Funding

62 Charitable donations via Barts Charity

63

64 **Research in context**

65 Evidence before this study

66 We searched PubMed, medRxiv, and bioRxiv for ["antibody" OR "serology"] AND ["SARS-CoV-2" OR 67 "COVID-19"]. The available literature highlights widespread use of serology to detect recent SARS-68 CoV-2 infection in individual patients and in population epidemiological surveys. Antibody to virus 69 spike protein S1 domain is widely reported to correlate with neutralising antibody titres. The existing 70 assays have good sensitivity to detect seroconversion within 14 days of incident infection, but the 71 available longitudinal studies have reported variable rates of decline in antibody levels and reversion 72 to undetectable levels in some people over 3 months. High frequency multi-time point serology data 73 for different antibody targets or assays in longitudinal cohorts from the time of incident infection to 74 greater than 3 months follow up are lacking.

75 Added value of this study

76 We combine detailed longitudinal serology using the Euroimmun anti-S1 and Roche anti-nucleocapsid 77 protein (NP) assays in 731 health care workers from the time of the first SARS-CoV-2 epidemic peak 78 in London, UK. In 157 seroconverters (using either assay) we show substantial heterogeneity in 79 semiquantitative antibody measurements over time between individuals and between assays. 80 Mathematical modelling of individual participant antibody production and clearance rates in individuals 81 with at least 8 data points over 21 weeks showed anti-S1 antibodies to have a faster clearance rate, 82 earlier transition from the initial antibody production rate to lower rates, and greater reduction in 83 antibody production rate after this transition, compared to anti-NP antibodies as measured by these 84 assays. As a result, Euroimmun anti-S1 measurements peaked earlier and then reduced more rapidly 85 than Roche anti-NP measurements. In this study, these differences led to 21% anti-S1 sero-reversion, 86 compared to 4% anti-NP sero-reversion over 4-5 months.

87 Implications of all of the available evidence

The rapid decline in anti-S1 antibodies measured by the Euroimmun assay following infection limits its application for diagnostic and epidemiological screening. If generalisable, these data are consistent with the hypothesis that anti-S1 mediated humoral immunity may not be sustained in some people beyond the initial post-infective period. Further work is required to understand the mechanisms behind the heterogeneity in antibody kinetics between individuals to SARS-CoV-2. Our data point to differential mechanisms regulating humoral immunity against these two viral targets.

94 Introduction

95 Detection of antibodies to SARS-CoV-2 is key to establishing the prevalence of infection in the 96 population, and hence tracking the progress of the pandemic, and may be used to diagnose past 97 infection in individual patients. Moreover, antibody to envelope spike protein may contribute to 98 protective immunity.¹⁻⁴ Interpretation of cross-sectional serology is critically dependent on 99 understanding the dynamics of the antibody response, and how this might vary for different viral target 100 antigens, in different assays and between individuals.

101 Numerous studies have shown that individuals with a confirmed polymerase chain reaction (PCR) 102 diagnosis of SARS-CoV-2 develop IgM, IgA and IgG against the spike protein S1 domain and 103 nucleocapsid protein (NP) within 2 weeks of symptom onset, which remain detectable following initial 104 viral clearance.⁵⁻⁷ Early data suggest antibody levels correlate with disease severity.^{8,9} Antibody 105 responses to other human coronaviruses decay over time with regular reinfection events, which has 106 caused concern that SARS-CoV-2 immunity following natural infection may be short-lived, leading to 107 risk of re-infection and making the possibility for achieving herd immunity through natural infection unrealistic.¹⁰⁻¹² The data for SARS-COV-2 remains conflicting, with some longitudinal serological 108 studies suggesting rapid antibody decline, while others have shown much greater persistence.^{3,13-22} 109 110 These vary by cohort (hospital, symptomatic only, PCR positive, community), assay (quality-assured, 111 antigen target), sampling granularity and follow-up period.

112 We present a detailed temporal analysis of circulating antibody using two widely used 113 semi-quantitative commercial assays to detect either anti-S1 or anti-NP in a cohort of hospital health 114 care workers in a prospective longitudinal multi-centre cohort study with high frequency serial 115 sampling over 16-21 weeks during the first epidemic wave in London, UK. We assessed concordance 116 between assays and the determinants of inter-individual heterogeneity in antibody responses by 117 testing associations with clinical and demographic variables. Finally, we applied mathematical 118 modelling to infer the fundamental mechanisms that may underpin changes to antibody levels over 119 time.

120 Methods

121 Study design and participants

122 The study was approved by a UK Research Ethics Committee (South Central - Oxford A Research 123 Ethics Committee, reference 20/SC/0149). The details of participant screening, study design, sample 124 collection, and sample processing are previously published and registered on ClinicalTrials.gov, NCT04318314.²³ Briefly, hospital healthcare workers (HCWs) self-declared fit to attend work were 125 126 recruited to an observational cohort study consisting of questionnaires and biological sample 127 collection at baseline and over 16 weekly-follow-up visits. Those who were unable to attend follow-up 128 visits were consulted remotely to enable capture of information regarding possible exposures and 129 symptoms. The baseline questionnaire included demographic data, medical history and exposures, 130 alongside detailed information regarding the nature and timing of self-reported symptoms over the preceding 3 months.²³ Follow-up weekly questionnaires included data on new symptoms and changes 131

to occupational and community risk factors, or results of tests conducted outside of the study.
Symptoms were classified as follows: 'case-defining' (fever, new dry cough or a new loss of taste or
smell; which have been shown to predict COVID-19 positivity with high specificity), 'non-specific
(symptoms other than case-defining symptoms), or asymptomatic (no symptoms reported throughout
the study period or in the three preceding months).

An initial cohort of 400 HCWs was recruited from St Bartholomew's Hospital, London, UK in the week 137 of lockdown in the United Kingdom (between 23rd and 31st March 2020); Cohort 1. Recruitment was 138 subsequently extended to include additional participants from multiple sites between 27th April 2020 139 140 and 7th May 2020 (Cohort 2). This included St Bartholomew's Hospital (n=101), NHS Nightingale 141 Hospital (n=10), and the Royal Free NHS Hospital Trust (n=220). Data collection therefore extended 142 over 21 weeks from baseline recruitment of Cohort 1 (the day of UK lockdown) to completion of 16-143 week follow-up of Cohort 2. Towards the end of the study period for Cohort 2 (follow-up weeks 12-15) 144 following the decline in community infection rates, the frequency of blood sampling was reduced to 145 twice per month rather than weekly, in order to improve tolerability to participants.

146 Procedures

147 Nasal RNA stabilizing swabs for molecular testing for SARS-CoV-2 were acquired at baseline and 148 weekly. RT-PCR was performed on nasal swabs using Roche cobas® SARS-CoV-2 test. SARS-CoV-149 2 antibody testing was performed in a single laboratory at Public Health England on all available 150 serum samples from baseline and follow-up visits using two commercial assays according to 151 manufacturers' protocols. These were the Euroimmun anti-SARS-CoV-2 enzyme-linked 152 immunosorbent assay (ELISA) (IgG) targeting IgG specific for the SARS-CoV-2 S1 antigen, and the 153 Roche Elecsys Anti-SARS-CoV-2 electrochemiluminescence immunoassay (ECLIA) that detects antibodies (including IgG) directed against the SARS-CoV-2 nucleocapsid protein (NP).²⁴⁻²⁷ 154

155 The Euroimmun ELISA was performed using a Stratec Gemini automated microplate processor as previously described.²⁸ Raw optical density (OD) readings were adjusted by calculating the ratio of the 156 157 OD of the control or participant sample divided by the OD of the assay calibrator. A ratio ≥1.1 was 158 used as the threshold for a positive result as per manufacturer's instructions.²⁴ A ratio of 11 was used as the upper threshold of the dynamic range, as the assay saturated above this point. The Roche 159 ECLIA was performed using the Roche cobas[®] e801 immunoassay analyser analyzer.²⁶ Results are 160 161 expressed as a cut-off index (COI), calculated by the analyser software as the 162 electrochemiluminescence signal obtained from the patient sample divided by the lot-specific cut-off value.²⁵ A COI≥1 was used as the threshold for a positive result as per manufacturer's instructions. 163 164 Across their dynamic range, the semi-quantitative indices of both assays approximate to a linear 165 relationship with antibody levels (Supplementary Figure 1). We have previously reported quantitation 166 of pseudovirus neutralising antibody (nAb) titres in 70 seropositive HCW from this cohort at 16-18 167 weeks of follow up.²⁹

168 Statistical analysis

In descriptive analyses, Spearman's rank correlation coefficients were calculated for all paired assay values across the study period. Univariable associations of demographics, symptoms and exposures with serostatus (seropositivity by one or both antibody assays at any timepoint) were assessed using logistic regression. Univariable and multivariable associations of characteristics (including age, sex, ethnicity and case-defining symptom status) with peak antibody levels were also quantified using linear regression for anti-N IgG/IgM and anti-S1 IgG.

175 We also performed univariable and multivariable survival analyses to assess whether participant 176 characteristics (including age, sex, ethnicity, case-defining symptom status and peak anti-S1) were 177 associated with time to sero-reversion for the anti-S1 assay. For this analysis, we included all 178 participants who seroconverted on the anti-S1 assay at any point during follow-up. We assumed 179 synchronous onset of infection for these individuals by indexing the start time for the survival analysis 180 as the first week of Cohort 1 study enrolment (the week of UK lockdown). Anti-S1 sero-reversion was 181 defined as a negative test in the last assay performed during follow-up for each participant. 182 Participants who sero-reverted exited the survival analysis on the first week where a negative test 183 (following an earlier positive test) was recorded; those who did not sero-revert were censored on the 184 week of their last available anti-S1 serology result. Analyses were conducted in R (version 3.6.3) and 185 Stata Statistical Software version 16 (College Station, TX, USA).

186 Mechanistic mathematical modelling of antibody production.

187 Circulating antibody levels are determined by the balance between rates of production and clearance. 188 We represented antibody production by a simplified discrete mechanistic model captured by 189 equation 1, with time indexed to calendar weeks from initiation of UK lockdown (as described for the 190 survival analyses). We incorporated a production rate (AbPr) and an antibody turnover (clearance 191 rate, r). Antibody production was simplified to two phases, an initial high rate (AbPr1) followed by a 192 switch to a lower rate (AbPr2), after a time t stop. Since the assay units of antibody concentration are 193 arbitrary and are not comparable between assays, the value of AbPr 1 is also arbitrary, and serves 194 only to scale the model output to the scale of the data. AbPr2 is expressed as a proportion of AbPr1. 195 The rate of clearance r can be directly calculated from the half-life, which was allowed to vary 196 between 1 week and 4 weeks (the latter equivalent to the known turnover rate of free IgG). An 197 important emerging feature of the model is that the time to plateau (peak) is determined only by the 198 clearance rate (Supplementary Figure 2), and not by the rate of production AbPr1. Furthermore, any 199 subsequent fall from the peak must reflect a corresponding decrease in AbPr. Hence the model 200 assumption that AbPr2<-AbPr1.

Equation 1: $Ab_t = Ab_{t-1} + AbPr - Ab_{t-1} * (1 - e^{-rt})$, where t is time in weeks, $AbPr = AbPr_1$ for 1 < t < 202 t_stop or AbPr_2 for t_stop < t < t_end; and AbPr2<AbPr1, and r = log(2)/half_life.

The levels of anti-S1 or anti-NP antibody in blood were compared to the model, over a range of the parameters (AbPr1, AbPr2 as a proportion of AbPr1, r and t_stop) by calculating the root mean

square distance between data and model output, and the parameter set with the minimum distance was selected. In our primary analysis, we restricted mathematical modelling to seropositive participants with ≥8 antibody data points (N=92 for anti-S1, N=86 for anti-NP, Supplementary Figure 3). In sensitivity analysis, we further restricted the modelling to seroconverters in whom the first (baseline) sample was negative.

210 Results

211 Study population

The study population has previously been published²³ and are summarised in Supplementary Table 1. 212 213 Briefly, this comprised 731 HCWs (median age 35 IQR 28 years, 33.0% male). Fourteen withdrew 214 (two with no samples obtained). Average weekly attendance was 61% with median 10 (IQR 6) visits 215 per participant. 20.2% were doctors, 31.2% were nurses, 27.5% were allied healthcare professionals, 216 21.1% were others including administrative and clerical. 22.6% worked in an intensive care unit or 217 emergency department setting. Co-morbidities were relatively low (18.1% smokers, 12.6% BMI>30kg/m², 10.7% with asthma, 7.3% with hypertension, 2.1% with diabetes mellitus, 1.2% with 218 219 rheumatological disease, 0.8% with cancer). 62.5% of participants were white, 37.5% non-white with 220 5.6% of black ethnicity), and 47.6% reported a mean household size of ≥3 people. Exposure at 221 baseline to contacts with confirmed COVID-19 was high (42.7% to patients, 29.5% to colleagues, and 222 1.1% to household members with confirmed COVID-19) and 25.6% were exposed to aerosol 223 generating procedures.

224 Seroconversion to SARS-CoV-2

In cohort 1 (recruited from 23rd March; day of UK lockdown), 28/396 (7.1%) had a positive nasal PCR at baseline, with rates falling rapidly in the subsequent four weeks, Figure 1.³⁰ In cohort 2 (recruited from 27th April, 5 weeks after UK lockdown and study start) 3/331 (0.9%) had positive nasal PCR swabs at their first study visit. There were no positive PCR swabs across either cohort by 6 weeks after UK lockdown (after 1st May 2020). The cumulative PCR positivity rate was 6.6% (48/729).

230 Serology testing used both assays on all subjects at all timepoints giving a total of 12990 tests and 231 median of 10 paired assays per individual (Supplementary Figure 3). Baseline seropositivity (by either 232 assay) in cohort 1 was 22/399 (5.5%), rising to 17.8% by study completion and 82/330 (25%) rising to 233 26.1% for cohort 2 (which started 5 weeks later). Overall, 157 of 729 (21.5%) had at least one 234 seropositive result. Consistent with the lack of nasal swab PCR detection of incident infection by 6 235 weeks after UK lockdown, 98% of cumulative seroconversions were evident by 7 weeks after 236 lockdown. Of the 48 participants in whom incident infection was detected by a positive nasal swab 237 PCR at any time point, 44 had subsequent blood tests of which 42/44 (95.4%) became seropositive in 238 at least one assay. Subsequent anti-S1 seropositivity at any timepoint was lower following a positive 239 PCR result than anti-NP seropositivity (86.4% versus 93.2% respectively), although the time interval 240 to seroconversion was faster (median 2.5 versus 3.0 weeks). Across all samples, binary outcomes at 241 the manufacturers' predefined thresholds for each assay were concordant in 96.9% (6276/6476

samples), but this reduced to 82.7% (953/1153) concordance in those samples where at least one ofthe two assays were positive.

244 Of participants who were seropositive at any timepoint, 43.9% reported case-definition symptoms 245 during the study, 24.8% non-case definition symptoms and 31.2% were completely asymptomatic. 246 Only two study participants were hospitalised, neither required ventilatory support or died. In 247 univariable analysis, there was no association between age or sex and seropositivity, but risk was 248 participants of Black ethnicity (odds ratio 2.61 [1.36, higher in 4.98], p=0.004, 249 Supplementary Figure 4). Risk of infection could not be explained by baseline co-morbidities or 250 clinical roles, although HCWs based in ICU had lower rates than others (OR 0.52 [0.30, 0.90], 251 p=0.02). Reported exposure to household members (baseline plus follow-up) with COVID-19 was the 252 strongest association with infection (OR 11.36 [2.27, 56.87], p=0.003). In contrast, reported exposure 253 to SARS-CoV-2 positive patients or colleagues did not influence infection rates.

254 Longitudinal serology to SARS-CoV-2

255 Peak antibody measurements were highly variable between seropositive individuals across the cohort 256 (coefficient of variation 77.89% for anti-NP and 54.09% for anti-S1, Figure 2). Despite infections being 257 mild, 7.7% participants had values at the threshold upper limit in the Euroimmun anti-S1 assay. We 258 extended our previous exploration of associations with peak antibody measurements in subset of the 259 cohort²⁹ to the full cohort of seropositive participants (Supplementary Table 1-3). In multivariable 260 analyses, there was a modest positive association of increasing age with peak anti-S1 antibody 261 measurements (beta coefficient per year increase 0.05; 95% CI 0.01 to 0.09; p=0.021), but not with 262 anti-NP (beta coefficient 0.50; 95% CI -0.22 to 1.2; p= 0.2). Black, Asian and minority ethnic groups 263 were associated with higher peak anti-NP responses (beta coefficient 22; 95% CI 4.9 to 39; p= 264 0.012), with a weaker association for peak anti-S1 (beta coefficient 1.0; 95% CI -0.04 to 2.0; p= 265 0.058). We found no association of peak antibody measurements with sex, or case-defining symptom 266 status.

267 Peak antibody measurements using the two assays correlated (r=0.57, p<0.001) (Supplementary 268 Figure 5). The correlation between ranked antibody indices stratified by time interval from the start of 269 the study, revealed a shift from more highly ranked anti-S1 antibodies in the first 6 weeks to more 270 highly ranked anti-NP antibodies in the last 8 weeks (Supplementary Figure 6A), and the ratio of 271 anti-S1:anti-NP antibody measurements trended downwards over time (Supplementary Figure 6B). 272 This analysis was consistent with different temporal profiles in circulating antibody levels to these two 273 targets. Accordingly, among seropositive participants, time ordered aggregate data for each assay 274 showed anti-S1 antibody indices to reach a peak and then fall more rapidly than the anti-NP antibody 275 indices (Figure 2). By the end of the study 31/143 (21.7%) with positive Euroimmun anti-S1 serology 276 had reverted to negative, in comparison to 6/150 (4%) of those with positive Roche anti-NP serology.

We compared previously reported neutralising antibody (nAb) titres in all seroconverters who attended for an additional blood sample (N=70) at 16-18 weeks of follow up^{29} to the highest anti-S1 and anti-NP assay measurements in the present study in 54/70 participants for whom we had data

from within two weeks of nAb measurements. The inhibitory concentration (IC)50 titres showed significant correlation to ranked anti-S1 antibody indices (r=0.57, p<0.0001) but not to anti-NP antibody indices at near-contemporary time points (Figure 3).

In univariable and multivariable survival analyses among participants who had a positive anti-S1 assay, higher peak anti-S1 responses were associated with longer time to sero-reversion (hazard ratio 0.42 per unit increase when adjusted for age, sex, ethnicity and case-defining symptom status; 95% CI 0.30 to 0.58; p<0.001; Supplementary Table 4). Age, sex, ethnicity and presence/absence of case-defining symptoms were not associated with time to sero-reversion.

288 Mathematical modelling of kinetics of circulating anti-S1 and anti-NP antibodies

We sought to obtain further insight into these underlying processes by fitting a mathematical model to the antibody data. We first fitted the model to the median of all the data for all individuals who were seropositive at any time point, assuming approximately synchronous infections coincident with the peak epidemic transmission at the start of the study. The best fit models for the anti-S1 and anti-NP data were clearly distinct. The inferred rate of clearance of S1 antibodies was faster than that of NP antibodies, and the switch to a lower antibody production rate occurred sooner and reduced by a greater extent (Figure 4A-B).

296 We noted that individual antibody response profiles were heterogenous in magnitude and dynamics 297 (Figure 2A). We therefore repeated our analysis for each subject individually (Supplementary 298 Figure 6), and derived the model parameters (Figure 4C-E). As anticipated, the best fit model 299 parameters across the cohort were highly heterogenous. However, clear differences could be 300 observed between the anti-S1 and anti-NP antibody responses, reflecting the same hierarchy as we 301 observed when fitting the median antibody data. Thus, anti-S1 antibodies have a shorter half-life 302 (median 2.5 weeks, 95% CI 2-3) than anti-NP antibodies (median 4 weeks, 95% CI 3-4). Production 303 switches to a lower rate more quickly (median 8 weeks, 95% CI 7-8 versus 13 weeks, 95% CI 13-14), 304 and to a relatively lower level (median 0.35, 95% Cl 0.2-0.5 versus 0.5, 95% Cl 0.05-0.5) with anti-S1 305 than with anti-NP antibodies, respectively. In general, there appeared to be greater inter-individual 306 heterogeneity in the best fit model parameters for the Euroimmun anti-S1 antibody profiles than for 307 the Roche anti-NP antibody profiles (Figure 4C-E). There were no strong associations between model 308 parameters (half-life of antibody clearance, time to lower production rate and level of reduction) for 309 either assay with age, sex, ethnicity or symptoms.

310 In order to exclude the potential confounding effects of capturing individuals only after antibody 311 production was well established, we repeated the analysis using only those who were seronegative at 312 the first available timepoint. The results were qualitatively the same for this smaller sub-group 313 (Supplementary Figure 8).

314 Discussion

315 We report a detailed time series analysis of circulating antibodies to SARS-CoV-2 S1 and NP proteins 316 following asymptomatic or pauci-symptomatic infection, using two widely adopted commercial assays. 317 Antibody measurements were highly heterogeneous between seropositive individuals, however both 318 assays show initial high sensitivity for incident (even asymptomatic) infections following PCR detection of virus on nasal swabs, consistent with previous evaluations of these tests.^{31 26,27} Peak 319 320 antibody index measurements in each assay were significantly correlated, suggesting both antigenic 321 targets were similarly immunogenic. By 16-21 weeks after the peak of the epidemic wave in London, 322 more than one in five individuals who had developed positive serology to the virus spike protein had 323 sero-reverted by the Euroimmun anti-S1 assay. In contrast, reduction in Roche anti-NP 324 measurements to subthreshold levels was evident in less than one in twenty. These findings have 325 potentially important implications. First, it reveals that epidemiological seroprevalence surveys may be 326 biased by antibody decay over this time horizon and may substantially underestimate incident 327 infections. Second, given that anti-S1 antibodies correlate with protective neutralising antibodies, the 328 extent of the reduction in circulating levels of anti-S1 suggests that antibody-mediated protective 329 immunity in some individuals may be short-lived following asymptomatic or pauci-symptomatic 330 infection.

331 Semi-quantitative antibody measurements over the initial five months following infection revealed 332 differential kinetics for the two assays. Anti-S1 antibodies reached peak levels before anti-NP 333 antibodies, but also showed a more rapid decline. It is interesting to speculate whether differential 334 profiles of antibody assays can be exploited to estimate the time of infection. We used mathematical 335 modelling to evaluate the determinants of the kinetic profiles and showed that the differential time to 336 peak antibody level is dependent on differential clearance rates. Our model is consistent with a 337 median half-life of 4 weeks for anti-NP antibodies consistent with long established estimates for 338 circulating IgG. The median half-life of anti-S1 antibodies was significantly less, at 2.5 weeks. The 339 subsequent fall in antibody levels reveals a transition in antibody production to a lower level. Our 340 model estimated that this transition occurred at a median of 8 weeks for anti-S1 antibodies compared 341 to a median of 14 weeks for anti-NP antibodies. Finally, we sought to derive the relative rate of 342 antibody production after the transition. For both antibodies, this reduced to at least 50% of antibody 343 production rates before the transition, but a substantial proportion of individuals exhibited significantly 344 greater reduction of anti-S1 antibody production. The combination of lower antibody production rate 345 and the natural clearance of antibody resulted in levels falling below the detection threshold of the 346 assay in a significant proportion of the study cohort. In multivariable analysis, only peak anti¹²S1 347 measurements were associated with shorter time to anti-S1 sero-reversion.

The durability of antibodies to specific antigenic targets is highly variable after different viral infections and the factors which determine these are poorly understood. Several hypotheses merit investigation in future work. If the surface exposed domains of the SARS-CoV-2 spike protein have greater propensity to form immune complexes, increased rates of antibody clearance via immune complex formations³² may contribute to the shorter half-life of anti-S1 antibodies. The transition to lower levels

353 of antibody production may represent the switch from antibody production from short lived plasmablasts to long lived plasma cells.³³ Importantly, immune complexes are also known to regulate 354 antibody production via inhibitory Fc receptors on plasma cells.³⁴ Therefore, immune complex 355 356 formation may also contribute to lower levels of anti-S1 antibody production after the transition. 357 Alternatively, there may be differences in the relative contribution of short-lived extrafollicular memory 358 B cells versus long-lived plasma cells to the antibody responses against these two antigens. We 359 found a stronger T cell response at 16-18 weeks to whole NP than whole spike antigen in this cohort²⁹; future studies should test whether NP-specific T follicular helper cells are better equipped to 360 361 support an efficient germinal centre reaction resulting in more long-lived plasma cells for NP than 362 spike protein. Alternatively, the better durability of anti-NP antibodies could relate to differences in 363 maintenance of their cognate antigen, for example on follicular dendritic cells.

364 A key strength of our study is that the start at the time of first epidemic peak in London, UK, allowed 365 the time of incident infection to be estimated accurately (69.0% of cohort 1 recruited prior to 366 seroconversion) and the data were not confounded by prior exposures or vaccine trials. In addition, 367 the focus on asymptomatic and pauci-symptomatic infection is representative of the vast majority of 368 incident infections. Our finding that almost one in three were completely free from symptoms despite 369 detailed weekly contemporaneous data collection to reduce recall bias is consistent with other 370 estimates of rates of asymptomatic infection.²² Serology was assessed weekly with a median of 10 samples per participant over 16 weeks and, with almost 13,000 validated antibody assays performed, 371 372 provide to our knowledge the most granular longitudinal data currently available at this scale.

373 Previous reports of the longevity of circulating antibodies to SARS-CoV-2 vary. Direct comparisons 374 are undermined by the use of different assays targeting distinct antigens, differences in study 375 population demographics, severity of illness, sampling frequency and duration of follow up. Two 376 themes have emerged. First, that there is a detectable rate of reversion of seropositive individuals to becoming seronegative over 3 to 6 months, consistent with our findings.^{3,18,19} Some reports have 377 sought to predict the time to sero-reversion with multilevel models to estimate the decay rate.^{20,35} Our 378 379 analysis extends these analyses significantly by combining unprecedented high frequency sampling 380 and mathematical modelling to provide dynamic estimates of production and clearance rates that 381 determine the overall levels of circulating antibody. Second, there are frequent reports of an 382 association between the clinical severity of infection with magnitude of initial antibody responses and the longevity of circulating antibody titres.^{15,35} Whether, this explains recent studies that show 383 sustained levels in hospitalised patients over 3 to 6 months will require further evaluation.^{2,36} 384

Our study has important limitations. Our time series analysis was limited to individual semiquantitative assays for each antigenic target. Direct comparison of antibody levels was not possible due to differences in dynamic range of these assays and their co-linearity. At present, results from any single assay are not generalisable. Moreover, these assays did not provide any differential assessment of antibody subclasses, which may exhibit differential kinetics. The significant correlation between near-contemporary Euroimmun anti-S1 measurements and functional pseudovirus nAb titres

391 increased confidence in our assessment of anti-S1 levels, and is in line with data using live virus micro-neutralisation.³⁷ Nonetheless, the correlation coefficient was modest suggesting that 392 393 Euroimmun anti-S1 measurements do not explain all humoral neutralising activity. Moreover, 394 emerging data on T cell reactivity to SARS-CoV-2 highlights the potential role of cellular immunity.^{16,29,38} Therefore, the Euroimmun anti-S1 measurements are not likely to provide a 395 396 comprehensive measure of protective immunity following natural infection. In addition, our study 397 population is not generalisable to all. Instead, it is representative of a workforce with likely high 398 exposure, and low risk of severe COVID-19. Cohort 1 may have underestimated rates of infection 399 because we were not able to recruit those who were in self-isolation at the peak of transmission, 400 whilst cohort 2 may have overestimated rates of infection due to volunteer bias seeking testing.³⁹ We 401 do not expect either of these to confound our key findings. The sample size limited stratification of 402 inter-individual heterogeneity, or identifying predictors of sero-reversion.

403 Conclusions

404 Asymptomatic and pauci-symptomatic infection with SARS-CoV-2 elicits antibody responses to spike 405 protein and to nuclear protein antigens in the vast majority, but with heterogeneity and differential 406 temporal profiles. Anti-S1 antibodies measured by the Euroimmun assay have a shorter half-life, 407 transition from high to lower levels of antibody production earlier and exhibit a greater reduction in 408 antibody production rate, compared to anti-NP antibodies measured by the Roche assay. The 409 important consequences of this are that, used alone, anti-S1 assays may underestimate past infection 410 with implications for the application of this test for individual patient care and population level 411 epidemiological surveys. Further work is required to evaluate the generalisability of these findings and 412 investigate the determinants of heterogeneity in these antibody responses.

413 References

Addetia A, Crawford KHD, Dingens A, et al. Neutralizing antibodies correlate with protection
 from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate. *medRxiv* 2020:
 2020.08.13.20173161.

417 2. Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 418 infection persist for months. *Science* 2020: eabd7728.

Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing
 antibody responses in the three months following SARS-CoV-2 infection in humans. *Nature Microbiology* 2020.

422 4. Yu J, Tostanoski LH, Peter L, et al. DNA vaccine protection against SARS-CoV-2 in rhesus 423 macaques. *Science* 2020; **369**(6505): 806.

424 5. Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2 425 seroconversion in humans. *Nature Medicine* 2020; **26**(7): 1033-6.

426 6. Long Q-X, Liu B-Z, Deng H-J, et al. Antibody responses to SARS-CoV-2 in patients with 427 COVID-19. *Nature Medicine* 2020; **26**(6): 845-8.

428 7. Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM. Severe acute
 429 respiratory syndrome coronavirus 2–specific antibody responses in coronavirus disease 2019
 430 patients. *Emerg Infect Dis* 2020.

431 8. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel 432 coronavirus disease 2019. *Clin Infect Dis* 2020.

433 9. Liu L, To KK, Chan KH, et al. High neutralizing antibody titer in intensive care unit patients 434 with COVID-19. *Emerg Microbes Infect* 2020; **9**(1): 1664-70.

435 10. Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2
436 infection and the potential for reinfection. *J Gen Virol* 2020; **101**(8): 791-7.

437 11. Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to 438 experimental coronavirus infection of man. *Epidemiol Infect* 1990; **105**(2): 435-46.

439 12. Edridge AWD, Kaczorowska J, Hoste ACR, et al. Seasonal coronavirus protective immunity is
 440 short-lasting. *Nat Med* 2020.

441 13. Chen Y, Tong X, Li Y, et al. A comprehensive, longitudinal analysis of humoral responses
442 specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients.
443 *PLoS Pathog* 2020; **16**(9): e1008796.

444 14. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid Decay of Anti–SARS-CoV-2 445 Antibodies in Persons with Mild Covid-19. *New England Journal of Medicine* 2020; **383**(11): 1085-7.

Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic
 SARS-CoV-2 infections. *Nature Medicine* 2020; **26**(8): 1200-4.

448 16. Rodda LB, Netland J, Shehata L, et al. Functional SARS-CoV-2-specific immune memory 449 persists after mild COVID-19. *medRxiv* 2020: 2020.08.11.20171843.

450 17. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral Immune Response to SARS-CoV-451 2 in Iceland. *N Engl J Med* 2020.

452 18. Muecksch F, Wise H, Batchelor B, et al. Longitudinal analysis of clinical serology assay 453 performance and neutralising antibody levels in COVID19 convalescents. *medRxiv* 2020.

454 19. Wu J, Liang B, Chen C, et al. SARS-CoV-2 infection induces sustained humoral immune 455 responses in convalescent patients following symptomatic COVID-19. *medRxiv* 2020: 456 2020.07.21.20159178.

457 20. Harris RJ, Whitaker HJ, Andrews NJ, et al. Serological surveillance of SARS-CoV-2: trends 458 and humoral response in a cohort of public health workers. *medRxiv* 2020: 2020.10.21.20216689.

Ripperger TJ, Uhrlaub JL, Watanabe M, et al. Orthogonal SARS-CoV-2 Serological Assays
 Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity.
 Immunity 2020.

462 22. Ward H, Atchison CJ, Whitaker M, et al. Antibody prevalence for SARS-CoV-2 in England 463 following first peak of the pandemic: REACT2 study in 100,000 adults. *medRxiv* 2020: 464 2020.08.12.20173690.

465 23. Augusto JB, Menacho K, Andiapen M, Bowles R. Healthcare Workers Bioresource: Study
466 outline and baseline characteristics of a prospective healthcare worker cohort to study immune
467 protection and pathogenesis in COVID-19. *Wellcome Open Res* 2020; **5**.

468 24. https://www.fda.gov/media/137609/download.

469 25. https://diagnostics.roche.com/global/en/products/params/elecsys-anti-sars-cov-2.html.

470 26. Ainsworth M, Andersson M, Auckland K, et al. Performance characteristics of five
471 immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. *The Lancet Infectious*472 *Diseases* 2020.

473 27. Pflüger LS, Bannasch JH, Brehm TT, et al. Clinical evaluation of five different automated
474 SARS-CoV-2 serology assays in a cohort of hospitalized COVID-19 patients. *J Clin Virol* 2020; **130**:
475 104549.

476 28. Evaluation of the Euroimmun Anti-SARS-CoV-2 ELISA (IgG) serology assay for the detection 477 of anti-SARS-CoV-2 antibodies: Public Health England, 2020.

478 29. Reynolds CJ, Swadling L, Gibbons JM, et al. Healthcare workers with mild / asymptomatic
479 SARS-CoV-2 infection show T cell responses and neutralising antibodies after the first wave.
480 *medRxiv* 2020: 2020.10.13.20211763.

- 481 30. Treibel TA, Manisty C, Burton M, et al. COVID-19: PCR screening of asymptomatic health-482 care workers at London hospital. *Lancet* 2020; **395**(10237): 1608-10.
- 483 31. Burbelo PD, Riedo FX, Morishima C, et al. Detection of Nucleocapsid Antibody to SARS484 CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients. *medRxiv* 2020:
 485 2020.04.20.20071423.
- 486 32. Benacerraf B, Sebestyen M, Cooper NS. The clearance of antigen antibody complexes from 487 the blood by the reticuloendothelial system. *J Immunol* 1959; **82**(2): 131-7.
- 488 33. Khodadadi L, Cheng Q, Radbruch A, Hiepe F. The Maintenance of Memory Plasma Cells.
 489 *Frontiers in Immunology* 2019; **10**: 721.
- Bournazos S, Wang TT, Dahan R, Maamary J, Ravetch JV. Signaling by Antibodies: Recent
 Progress. Annual Review of Immunology 2017; 35(1): 285-311.
- 492 35. Grandjean L, Saso A, Ortiz A, et al. Humoral Response Dynamics Following Infection with 493 SARS-CoV-2. *medRxiv* 2020: 2020.07.16.20155663.
- 494 36. Iyer AS, Jones FK, Nodoushani A, et al. Dynamics and significance of the antibody response 495 to SARS-CoV-2 infection. *medRxiv* 2020.
- 496 37. Harvala H, Mehew J, Robb ML, et al. Convalescent plasma treatment for SARS-CoV-2
 497 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020. *Euro Surveill* 2020;
 498 25(28): 2001260.
- 499 38. Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T Cell Immunity in Convalescent 500 Individuals with Asymptomatic or Mild COVID-19. *Cell* 2020; **183**(1): 158-68 e14.
- 501 39. Nguyen LH, Drew DA, Graham MS, et al. Risk of COVID-19 among front-line health-care 502 workers and the general community: a prospective cohort study. *The Lancet Public Health* 2020.

503 Footnotes

504 Data Sharing Statement

505 The COVIDsortium Healthcare Workers consortium was prospectively designed to create a 506 bioresource with high-dimensional sampling including viral PCR swabs, serology and PBMCs over an 507 initial 20 weeks and pending 6-month and 1 year timepoints (study protocol has been published and is available online https://covid-consortium.com).²³ Applications for access to the individual participant 508 509 de-identified data (including data dictionaries) and samples can be made to the access committee via 510 an online application https://covid-consortium.com/application-for-samples/. Each application will be 511 reviewed, with decisions to approve or reject an application for access made on the basis of (i) 512 accordance with participant consent and alignment to the study objectives (ii) evidence for the 513 capability of the applicant to undertake the specified research and (iii) availability of the requested 514 samples. The use of all samples and data will be limited to the approved application for access and 515 stipulated in the material and data transfer agreements between participating sites and investigators 516 requesting access.

517 Role of the funding source

Funding for COVIDsortium was donated by individuals, charitable Trusts, and corporations including
Goldman Sachs, Citadel and Citadel Securities, The Guy Foundation, GW Pharmaceuticals, Kusuma
Trust, and Jagclif Charitable Trust, and enabled by Barts Charity with support from UCLH Charity.
Wider support is acknowledged on the COVIDsortium website. Institutional support from Barts Health
NHS Trust and Royal Free NHS Foundation Trust facilitated study processes, in partnership with

523 University College London and Queen Mary University London. Serology tests (anti-S1 and anti-NP) 524 were funded by Public Health England.

525 JCM, CM and TAT are directly and indirectly supported by the University College London Hospitals 526 (UCLH) and Barts NIHR Biomedical Research Centres and through the British Heart Foundation 527 (BHF) Accelerator Award (AA/18/6/34223). TAT is funded by a BHF Intermediate Research 528 Fellowship (FS/19/35/34374). MN is supported by the Wellcome Trust (207511/Z/17/Z) and by NIHR 529 Biomedical Research Funding to UCL and UCLH. RJB/DMA are supported by MRC Newton 530 (MR/S019553/1 and MR/R02622X/1), NIHR Imperial Biomedical Research Centre (BRC):ITMAT, 531 Cystic Fibrosis Trust SRC, and Horizon 2020 Marie Curie Actions. MKM is supported by the 532 UKRI/NIHR UK-CIC grant, a Wellcome Trust Investigator Award (214191/Z/18/Z) and a CRUK 533 Immunology grant (26603) AM is supported by Rosetrees Trust, The John Black Charitable 534 Foundation, and Medical College of St Bartholomew's Hospital Trust. RKG is funded by National 535 Institute for Health Research (DRF-2018-11-ST2-004).

536 The funders had no role in study design, data collection, data analysis, data interpretation, or writing 537 of the report. The corresponding author had full access to all the data in the study and had final 538 responsibility for the decision to submit for publication.





Figure 1. Longitudinal infection with SARS-COV-2 over 21 weeks across 731 healthcare workers.

Results from testing for SARS-CoV-2 by cohort showing weekly PCR percentage positivity (weekly results, 95% CI) and seropositivity (cumulative percentage using combined anti-S1 IgG and anti-NP IgM/IgG, standard error).



Figure 2. Longitudinal antibody responses across all timepoints in participants seropositive at any timepoint

Individual participant data (left) and time ordered aggregate data (right) for Euroimmun anti-S1 antibody assay (**A-B**) and Roche combined anti-NP antibody assay (**C-D**) showing the heterogeneity in antibody responses between individuals and the differences in antibody kinetics between assays, with an earlier peak and decline in anti-S1 compared with anti-NP antibodies.



Figure 3. Correlation of anti-S1 and anti-NP antibody measurements with neutralising antibody titres at 16-18 weeks.

Comparison of neutralising antibody (nAb) titres represented as 50% inhibitory concentrations (IC) with Euroimmun anti-S1 levels (A) and Roche anti-NP levels (B) in 54 participants with nAb measurements and near-contemporaneous (\pm 2 weeks) Euroimmun and Roche serology. R and p values by Spearman rank correlations.













Figure 3



Figure 4

